These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34822010)

  • 1. Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines.
    Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
    Metabolomics; 2021 Nov; 17(12):104. PubMed ID: 34822010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
    Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
    Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
    J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic KRAS suppresses store-operated Ca
    Pierro C; Zhang X; Kankeu C; Trebak M; Bootman MD; Roderick HL
    Cell Calcium; 2018 Jun; 72():70-80. PubMed ID: 29748135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS
    Charitou T; Srihari S; Lynn MA; Jarboui MA; Fasterius E; Moldovan M; Shirasawa S; Tsunoda T; Ueffing M; Xie J; Xin J; Wang X; Proud CG; Boldt K; Al-Khalili Szigyarto C; Kolch W; Lynn DJ
    Br J Cancer; 2019 Jul; 121(1):37-50. PubMed ID: 31133691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer.
    Hutton JE; Wang X; Zimmerman LJ; Slebos RJ; Trenary IA; Young JD; Li M; Liebler DC
    Mol Cell Proteomics; 2016 Sep; 15(9):2924-38. PubMed ID: 27340238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells.
    Doubleday PF; Fornelli L; Ntai I; Kelleher NL
    FEBS J; 2021 Dec; 288(23):6683-6699. PubMed ID: 34227245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
    Modest DP; Camaj P; Heinemann V; Schwarz B; Jung A; Laubender RP; Gamba S; Haertl C; Stintzing S; Primo S; Bruns CJ
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):953-61. PubMed ID: 23455880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting metabolic reprogramming in KRAS-driven cancers.
    Kawada K; Toda K; Sakai Y
    Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation-Specific and Common Phosphotyrosine Signatures of
    Tahir R; Renuse S; Udainiya S; Madugundu AK; Cutler JA; Nirujogi RS; Na CH; Xu Y; Wu X; Pandey A
    J Proteome Res; 2021 Jan; 20(1):670-683. PubMed ID: 32986951
    [No Abstract]   [Full Text] [Related]  

  • 11. In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.
    Riffo-Campos ÁL; Castillo J; Vallet-Sánchez A; Ayala G; Cervantes A; López-Rodas G; Franco L
    Oncol Rep; 2016 Dec; 36(6):3627-3634. PubMed ID: 27805251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
    JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
    Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
    PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
    Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
    Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
    Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driver gene KRAS aggravates cancer-associated stroke outcomes.
    Yan H; Sasaki T; Gon Y; Nishiyama K; Kanki H; Mochizuki H
    Thromb Res; 2024 Jan; 233():55-68. PubMed ID: 38029547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background.
    Budagyan K; Chernoff J
    Methods Mol Biol; 2021; 2262():323-334. PubMed ID: 33977487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines.
    Stubbs CK; Biancucci M; Vidimar V; Satchell KJF
    Sci Rep; 2021 Sep; 11(1):17925. PubMed ID: 34504197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.